Previous 10 | Next 10 |
Completed successful initial public offering and raised $46 million in gross proceeds --- Appointed four new independent board of directors to strengthen leadership team --- Signed a multi-target collaboration agreement with Zentalis Pharmaceuticals (Nasdaq: ZNTL) to d...
Compounds reverse the neurodegenerative process observed in a Parkinson’s disease in vivo model Compounds are novel allosteric regulators that bind, stabilize and restore activity of mutated GCase Compounds decrease both phosphorylated and aggregated α ...
BETHESDA, Md., April 27, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced that Eric...
BETHESDA, Md., April 22, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced a poster...
Gain Therapeutics ([[GANX]]) announces a multi-target collaboration agreement with Zentalis Pharmaceuticals ([[ZNTL]] -0.7%) to discover new product candidates for the treatment of cancer.Under the terms of the agreement, Gain will pursue binding site identification on target protei...
Collaboration to use Gain’s proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) computational platform technology to identify new and previously difficult-to-drug oncology targets BETHESDA, Md., April 20, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc...
HOUSTON, April 14, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc., (Coya™), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Tregs) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune disease...
Piper Sandler paints an upbeat outlook for the synthetic biology (SynBio) space as the firm initiates coverage on Codexis (CDXS) and Twist Biosciences (TWST).Twist Bioscience and Codexis in focus as Piper Sandler sizes up synthetic biologyThe analyst Steven Mah predict the global market for s...
BETHESDA, Md., March 25, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”) today announced the closing of its initial public offering of 3,636,364 shares of its common stock and full exercise of the underwriters’ overallotment option to purchase 545,454 addition...
Last week was a busy one for the IPO market with 11 IPOs raising $3 billion, joined by 24 SPACs that brought another $8.4 billion to the table. Chinese IoT platform developer Tuya Inc (NYSE: TUYA) raised $915 million at an $11.8 billion market cap. It supplies businesses and develop...
News, Short Squeeze, Breakout and More Instantly...
Gain Therapeutics Inc. Company Name:
GANX Stock Symbol:
NASDAQ Market:
Gain Therapeutics Inc. Website:
GT-02287 Well Tolerated With No Serious Adverse Events or Other Safety Signals Reported Additional Topline Data To Be Presented Mid-August GT-02287 on Track To Initiate Clinical Trial in Parkinson’s Disease Patients in Q4 2024 BETHESDA, Md., July 09, 2024 (GLOBE NEWSW...
BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announc...